[go: up one dir, main page]

AR067420A1 - Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan - Google Patents

Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan

Info

Publication number
AR067420A1
AR067420A1 ARP080102894A ARP080102894A AR067420A1 AR 067420 A1 AR067420 A1 AR 067420A1 AR P080102894 A ARP080102894 A AR P080102894A AR P080102894 A ARP080102894 A AR P080102894A AR 067420 A1 AR067420 A1 AR 067420A1
Authority
AR
Argentina
Prior art keywords
irinotecan
growth factor
vegf
endotelial
antitumoral
Prior art date
Application number
ARP080102894A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Marielle Chiron-Blondel
Pascal Lejeune
Patricia Vrignaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067420(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR067420A1 publication Critical patent/AR067420A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Combinaciones antitumorales constituidas por un inhibidor de VEGF (factor de crecimiento vascular endotelial) asociadas a irinotecan terapéuticamente utiles en el tratamiento de enfermedades neoplásicas. Reivindicacion 4: Productos que contienen un inhibidor de VEGF y de irinotecan en el tratamiento de enfermedades neoplásicas como preparacion combinada para una utilizacion simultánea, separada o escalonada en el tiempo en terapia anticancerígena.
ARP080102894A 2007-07-05 2008-07-04 Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan AR067420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0704868A FR2918279B1 (fr) 2007-07-05 2007-07-05 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (1)

Publication Number Publication Date
AR067420A1 true AR067420A1 (es) 2009-10-07

Family

ID=38961256

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102894A AR067420A1 (es) 2007-07-05 2008-07-04 Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan

Country Status (24)

Country Link
US (3) US20100160233A1 (es)
EP (1) EP2173349B1 (es)
JP (4) JP2010532335A (es)
KR (4) KR20180105261A (es)
CN (3) CN101686975A (es)
AR (1) AR067420A1 (es)
AT (1) ATE500829T1 (es)
AU (1) AU2008290442B2 (es)
BR (1) BRPI0812835B8 (es)
CA (1) CA2693152C (es)
CY (1) CY1111675T1 (es)
DE (1) DE602008005457D1 (es)
DK (1) DK2173349T3 (es)
ES (1) ES2362637T3 (es)
FR (1) FR2918279B1 (es)
HR (1) HRP20110432T1 (es)
IL (2) IL203132A (es)
MX (1) MX2009013950A (es)
PL (1) PL2173349T3 (es)
PT (1) PT2173349E (es)
RS (1) RS51777B (es)
RU (1) RU2471483C2 (es)
SI (1) SI2173349T1 (es)
WO (1) WO2009024667A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122012021252B8 (pt) 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
ES2704986T3 (es) * 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) * 2009-09-15 2013-01-31 John Ryan Treatment of cancer
BR112013017752A8 (pt) 2011-01-13 2018-01-09 Regeneron Pharma uso de um antagonista do vegf e formulação farmacêutica
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
PT3170005T (pt) 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
EP3716992B1 (en) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
MXPA04008484A (es) * 2002-03-01 2004-12-06 Pharmacia Italia Spa Forma polimorfica cristalina de clorhidrato de irinotecano.
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Also Published As

Publication number Publication date
BRPI0812835A2 (pt) 2014-12-09
KR20100031123A (ko) 2010-03-19
HRP20110432T1 (hr) 2011-07-31
RU2010103781A (ru) 2011-08-10
DE602008005457D1 (de) 2011-04-21
BRPI0812835B8 (pt) 2021-05-25
JP2017052789A (ja) 2017-03-16
FR2918279B1 (fr) 2010-10-22
DK2173349T3 (da) 2011-06-27
JP2014240422A (ja) 2014-12-25
WO2009024667A3 (fr) 2009-04-23
EP2173349A2 (fr) 2010-04-14
MX2009013950A (es) 2010-03-09
ES2362637T3 (es) 2011-07-08
US20190275147A1 (en) 2019-09-12
KR20150048910A (ko) 2015-05-07
CA2693152C (fr) 2019-02-26
WO2009024667A2 (fr) 2009-02-26
US20140127202A1 (en) 2014-05-08
JP2010532335A (ja) 2010-10-07
IL240965A0 (en) 2015-10-29
RS51777B (sr) 2011-12-31
KR20180105261A (ko) 2018-09-27
AU2008290442B2 (en) 2013-06-27
CN105833244A (zh) 2016-08-10
IL203132A (en) 2015-09-24
CY1111675T1 (el) 2015-10-07
EP2173349B1 (fr) 2011-03-09
RU2471483C2 (ru) 2013-01-10
CN103623392A (zh) 2014-03-12
CA2693152A1 (fr) 2009-02-26
BRPI0812835B1 (pt) 2020-09-08
PT2173349E (pt) 2011-06-02
CN101686975A (zh) 2010-03-31
FR2918279A1 (fr) 2009-01-09
ATE500829T1 (de) 2011-03-15
PL2173349T3 (pl) 2011-08-31
US20100160233A1 (en) 2010-06-24
KR20160079918A (ko) 2016-07-06
JP2019006785A (ja) 2019-01-17
AU2008290442A1 (en) 2009-02-26
SI2173349T1 (sl) 2011-06-30

Similar Documents

Publication Publication Date Title
AR067420A1 (es) Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan
ECSP12012106A (es) Terapia antiviral
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
ECSP109934A (es) Compuesto - 946
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
MX2010001401A (es) Productos medicos mejorados, revestidos con preparaciones farmaceuticas, la produccion de los mismos y el uso de los mismos.
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2014006762A (es) Metodos para el tratamiento de desordenes cardiovasculares.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
NI201100192A (es) Combinación antitumoral que compprende cabazitaxel y capecitabina
GB201014391D0 (en) Drug composition and its use in therapy
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos

Legal Events

Date Code Title Description
FC Refusal